On this page
What is Bullous Pemphigoid?
Bullous pemphigoid is an autoimmune skin disease characterized by the development of erythematous (red) skin lesions that, after several days, evolve into large, tense blisters (bullae) that can reach several centimeters in diameter. Lesions are predominantly located on the limbs and trunk and are frequently associated with intense itching (pruritus).
Being an autoimmune disease, bullous pemphigoid results from a malfunction of the immune system: the body produces autoantibodies that, instead of protecting it from bacteria and viruses, attack and damage its own skin structures. Specifically, they target the basement membrane zone that anchors the epidermis to the underlying dermis.
Epidemiology
Bullous pemphigoid is the most common autoimmune blistering disease. The incidence is approximately 10 cases per million inhabitants per year, making it a rare condition overall. However, its incidence has been increasing, largely due to the aging population. It predominantly affects elderly individuals, though cases in children have been reported. It affects men and women with equal frequency.
Associated Neurological and Psychiatric Conditions
A clinically important association is that 30–50% of bullous pemphigoid cases occur in patients with underlying neurological or psychiatric conditions, including:
- Epilepsy
- Stroke (cerebrovascular disease)
- Parkinson’s disease
- Depression
This association is thought to reflect shared antigens between the nervous system and the skin’s basement membrane zone, or common immune dysregulation pathways.
Course and Prognosis
Bullous pemphigoid follows a chronic, relapsing-remitting course, with prolonged periods of remission alternating with disease flares. These flares are generally less severe than the initial episode. Without treatment, extensive blistering can lead to serious complications, including dehydration and significant protein loss, which is particularly dangerous in very elderly patients.
With appropriate treatment, lesions typically heal without scarring; only rarely do residual hyperpigmented spots or small milia (tiny keratin cysts) persist.
Is Bullous Pemphigoid Contagious?
Bullous pemphigoid is NOT:
- Contagious: it cannot be transmitted to other people through any form of contact
- Caused by an allergy: it is an autoimmune disease, not an allergic reaction
- Influenced by diet or lifestyle: no specific dietary factors have been shown to cause or aggravate the condition
Cause
Bullous pemphigoid is caused by the production of autoantibodies directed against two specific proteins of the basement membrane zone (BMZ), the structural layer that separates the epidermis (the outer skin layer) from the dermis (the deeper skin layer):
- BP230 (bullous pemphigoid antigen 1 / BPAG1): a protein located within the hemidesmosome (the adhesion complex anchoring basal keratinocytes to the basement membrane)
- BP180 (bullous pemphigoid antigen 2 / BPAG2 / type XVII collagen): a transmembrane protein that extends through the basement membrane. It is the primary target antigen in most patients
When autoantibodies bind to these proteins, they activate the complement cascade and recruit inflammatory cells (particularly eosinophils and neutrophils) to the BMZ. The resulting inflammatory reaction disrupts the structural integrity of the basement membrane, causing separation of the epidermis from the dermis and creating the characteristic subepidermal blisters of bullous pemphigoid.
Risk Factors
Like most autoimmune diseases, bullous pemphigoid does not have clearly defined causal risk factors. The prevailing understanding is that the disease results from a combination of genetic predisposition and environmental triggers. The following factors have been associated with increased risk or disease triggering:
Medications: certain drugs have been implicated as triggers
- Antibiotics: Penicillin, ampicillin
- Diuretics: Furosemide, spironolactone
- Antipsychotics
- DPP-4 inhibitors (gliptins, e.g., vildagliptin) are used in type 2 diabetes and have a well-documented association
- Checkpoint inhibitors (e.g., pembrolizumab, nivolumab): oncological immunotherapy drugs increasingly linked to drug-induced bullous pemphigoid
Physical factors:
- Ultraviolet light (UV) radiation
- Radiotherapy
- Skin trauma or surgical procedures
Skin conditions:
- Skin infections
- Psoriasis
- Lichen planus
Systemic diseases:
- Parkinson’s disease (the strongest neurological association)
- Diabetes mellitus
- Multiple sclerosis
- Rheumatoid arthritis
- Ulcerative colitis
Paraneoplastic association (rare): Occasionally, bullous pemphigoid may be a paraneoplastic phenomenon, a manifestation of an underlying visceral malignancy, particularly gastrointestinal carcinomas. In these cases, the skin disease may precede, coincide with, or follow the diagnosis of cancer.
Symptoms
The clinical presentation of bullous pemphigoid evolves through two recognizable phases:
Phase 1: Prodromal (Pre-Bullous) Phase
The prodromal phase may last weeks to months before true blisters develop. It is characterized by:
- Erythematous (red) patches: variable in size, sometimes urticarial (hive-like) in appearance
- Intense pruritus (itching): often the dominant and most distressing symptom, present before any visible lesions
- In some patients, this non-bullous phase may persist as the only manifestation for months or even years without progression to blistering
- In others, no prodromal rash is observed before blisters appear
Phase 2: Bullous Phase
The bullous phase is characterized by the appearance of the classic skin lesions:
- Large, tense bullae: These measure from a few millimeters to several centimeters in diameter. The tense (rather than flaccid) character of the blisters reflects their subepidermal (rather than intraepidermal) location, which is a key distinguishing feature from pemphigus vulgaris
- Blisters contain clear serous or serosanguineous (blood-tinged) fluid
- Arise on erythematous and/or edematous skin
- May persist intact for several days before rupturing
- Upon rupture: leave superficial erosions covered by yellowish-brown or dark crusts, which heal progressively, usually without scarring
Distribution
The characteristic distribution of bullous pemphigoid lesions is:
- Limbs (inner thighs, forearms, axillae, particularly intertriginous or flexural areas)
- Abdomen
- Skin folds
- Face and scalp are typically spared (an important diagnostic clue)
- Mucous membrane involvement (oral, conjunctival, genital) occurs in only a minority of cases (approximately 10–30%) and is generally milder than in pemphigus vulgaris
Special Forms
- Vesicular form: Less common; characterized by small vesicles (rather than large bullae) predominantly on the hands, with intense pruritus
- Pemphigoid gestationis (pemphigoid of pregnancy): A specific variant that develops during the 2nd or 3rd trimester of pregnancy or in the postpartum period; associated with significant risks to the fetus (see below)
- Mucous membrane-predominant form: Primarily involves mucous membranes; cutaneous involvement is exceptional
Prognosis
Despite the chronicity of the disease and potentially lengthy treatment courses, the overall prognosis of bullous pemphigoid is generally favorable. Most patients achieve remission with treatment, and the skin heals without permanent damage. Mortality is primarily related to complications of therapy (particularly prolonged corticosteroid use in elderly patients) rather than to the disease itself.
Complications
Infectious Complications
The primary complication of bullous pemphigoid is secondary infection of the open erosions. The blistered, denuded skin provides an ideal portal of entry for bacterial and fungal pathogens. Serious skin infections, including cellulitis and septicemia, can develop, particularly in elderly or immunocompromised patients.
Preventive measures include daily wound care with antiseptic solutions and prompt treatment of any signs of infection.
Treatment-Related Complications
In elderly patients, long-term corticosteroid therapy carries significant risks:
- Osteoporosis increases fracture risk. Calcium, vitamin D supplementation, and bisphosphonate therapy are often co-prescribed
- Diabetes mellitus or worsening of pre-existing diabetes (steroid-induced hyperglycemia)
- Hypertension
- Susceptibility to infections (due to immunosuppression)
- Gastric ulceration (gastroprotection with proton pump inhibitors is routinely co-prescribed)
- Adrenal suppression with prolonged use
Complications in Pregnancy
Pemphigoid gestationis carries risks of preterm birth and neonatal pemphigoid (transient blistering in the newborn due to transplacental transfer of maternal autoantibodies, which typically resolves spontaneously within weeks as maternal antibodies clear from the infant’s circulation).
Diagnosis
The diagnosis of bullous pemphigoid can be challenging, particularly in the early prodromal phase when blisters have not yet appeared. The diagnostic workup combines clinical evaluation, laboratory testing, and skin biopsy.
Clinical Evaluation
The clinician evaluates the following features of the skin lesions:
- Morphology: Tense bullae on erythematous or urticarial skin (vs. flaccid bullae in pemphigus)
- Distribution: Predominantly limbs and abdomen; sparing of the face, head, and neck
- Extent of disease and rate of evolution
- Pruritus intensity
- Nikolsky sign NEGATIVE in bullous pemphigoid: Applying gentle lateral pressure to the normal skin adjacent to a blister does not cause epidermal detachment. This negative result is diagnostically important, as it distinguishes bullous pemphigoid from pemphigus vulgaris, where the Nikolsky sign is positive (lateral pressure easily detaches the superficial epidermis due to intraepidermal acantholysis)
Laboratory Tests
Blood tests are useful for detecting the circulating autoantibodies responsible for bullous pemphigoid. Key findings include:
- Anti-BP180 (NC16A domain) and anti-BP230 antibody titers, detected by ELISA (enzyme-linked immunosorbent assay), are the standard serological tests for bullous pemphigoid. Note: antibody levels do not always correlate reliably with disease activity
- Eosinophilia: elevated eosinophil count on complete blood count (CBC), a characteristic though non-specific finding in active bullous pemphigoid
- Indirect immunofluorescence (IIF): Detects circulating anti-BMZ antibodies in the patient’s serum using a substrate tissue (normal human skin); positive in the majority of patients
Skin Biopsy
Biopsy is the cornerstone of definitive diagnosis:
Histopathology (Standard Light Microscopy)
A biopsy of a fresh blister reveals:
- Subepidermal blister: the cleavage plane is below the epidermis, at the level of the basement membrane zone. This distinguishes bullous pemphigoid from pemphigus, where the split is intraepidermal
- Eosinophil-rich inflammatory infiltrate in the dermis and within the blister fluid
- Intact, non-acantholytic basal keratinocytes lining the blister roof
Direct Immunofluorescence (DIF): Gold Standard
A biopsy of perilesional (clinically normal) skin adjacent to a blister is processed for immunofluorescence and reveals:
- Linear deposits of IgG and/or C3 (complement component 3) along the basement membrane zone, a finding that is present in virtually all patients with active bullous pemphigoid and is considered the diagnostic gold standard
- The linear pattern of deposition distinguishes bullous pemphigoid from pemphigus (where deposits are intercellular throughout the epidermis in a “fishnet” pattern) and from other subepidermal blistering diseases
Treatment and Therapy
Treatment aims to suppress blister formation, relieve itching, promote healing of erosions, and prevent complications, while minimizing treatment-related side effects, especially in the predominantly elderly patient population.
Corticosteroids: First-Line Treatment
Corticosteroids (cortisone) remain the mainstay of bullous pemphigoid therapy. Route and dosage depend on disease extent and severity:
Topical Corticosteroids (Localized Disease)
For limited disease with few blisters or slow progression, high-potency topical corticosteroids (e.g., clobetasol propionate 0.05% cream) applied daily over extensive body surface areas are preferred. Large multicenter studies (particularly from France) have demonstrated that topical superpotent corticosteroids are at least as effective as oral corticosteroids for extensive disease, with a significantly better safety profile, especially regarding systemic side effects in elderly patients.
Systemic (Oral) Corticosteroids (Generalized Disease)
For widespread disease, systemic therapy with oral prednisone is used:
- Starting dose: Typically 0.5–1 mg/kg/day
- Once blister formation stops and lesions begin to heal, the dose is gradually tapered over months
- Gastroprotection (proton pump inhibitor), calcium and vitamin D supplementation, and osteoporosis prevention should be co-prescribed routinely
Corticosteroids work by suppressing autoantibody production and reducing the inflammatory response at the BMZ, leading to disappearance of pruritus and blisters typically within 2–4 weeks.
Steroid-Sparing Immunosuppressants
When corticosteroids alone are insufficient, when lesions are particularly extensive, or to reduce steroid-related toxicity during maintenance, adjuvant immunosuppressants are added:
- Methotrexate, particularly used in elderly patients due to its favorable efficacy and tolerability profile in bullous pemphigoid
- Azathioprine
- Mycophenolate mofetil
- Cyclophosphamide: reserved for severe, refractory cases
Emerging and Alternative Therapies
Accumulating evidence supports the use of newer therapeutic options, particularly in refractory or severe cases:
- Rituximab, an anti-CD20 monoclonal antibody, depletes B lymphocytes responsible for autoantibody production. Increasingly used in refractory bullous pemphigoid with encouraging results.
- Intravenous immunoglobulins (IVIG) may accelerate reduction of circulating autoantibody levels and shorten disease duration. They are used as an adjunct in selected cases
- Omalizumab (anti-IgE) is under investigation given the role of IgE autoantibodies and eosinophil activation in bullous pemphigoid pathophysiology
- Dupilumab (anti-IL-4/IL-13): reports of efficacy in bullous pemphigoid are emerging from case series and small studies
Wound Care and Supportive Measures
Daily wound care with antiseptic solutions (e.g., dilute chlorhexidine, povidone-iodine) is essential to:
- Prevent bacterial superinfection of erosions
- Promote healing
Adequate hydration must be ensured, particularly in elderly patients with extensive erosions, where significant fluid and protein losses can lead to dangerous dehydration and electrolyte imbalance.
Sources and Bibliography
- Fitzpatrick TB, et al. Fitzpatrick’s Dermatology in General Medicine. Manual and Atlas of Clinical Dermatology. 2014.
- Cainelli T., Giannetti A., Rebora A. Manuale di dermatologia medica e chirurgica. McGraw-Hill, 2017.
- Kasperkiewicz M, et al. “The pathophysiology of bullous pemphigoid”. Clinical Reviews in Allergy & Immunology. 2007.
- Joly P, et al. “A comparison of oral and topical corticosteroids in patients with bullous pemphigoid”. New England Journal of Medicine. 2002;346(5):321–327.
- Murrell DF, et al. “Diagnosis and management of bullous pemphigoid: recommendations of an international panel of experts”. Journal of the American Academy of Dermatology. 2020;82(3):575–585.
- PMC: New therapeutic approaches for bullous pemphigoid
- PubMed: Alternative therapies in bullous pemphigoid
- DermNet NZ Bullous Pemphigoid
- British Association of Dermatologists Bullous Pemphigoid Guidelines
